PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37882758.
- Also identified by DOI 10.1097/RLU.0000000000004919.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
Medical subject headings
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant